Biogen announces its intention to reprioritize its resources in Alzheimer's disease (AD), where it will continue to advance its Leqembi and accelerate the development of potential treatment modalities, including BIIB080 and BIIB113.

On the other hand, the Group will terminate the development and commercialization of Aduhelm 100 mg/mL injectable for intravenous use, as well as the Envision clinical trial, a decision that is not related to safety or efficacy issues.

Biogen has recorded a non-recurring charge of approximately $60 million related to the costs of closing this program in the fourth quarter of 2023. A large part of the resources thus freed up will be redeployed in its AD franchise.

Copyright (c) 2024 CercleFinance.com. All rights reserved.